Merus NV【MRUS】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

40.47

買値

40.34

売値

40.46

出来高

144,137

39.645 日の範囲 40.8199

33.8301 52 週間の範囲 61.61

時価総額

2.771B

前日終値

40.40

始値

40.38

時刻

40.33

最終取引時間

02:59:36

財務取引量

US$ 5,826,031

VWAP

40.4201

平均取引量 (3 か月)

628,354

発行済株式数

68,463,681

配当利回り

PER

0.00

1 株当たり利益 (EPS)

歳入

43.95M

純利益

-154.94M

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. 詳細を表示

セクター

Gen Med & Surgical Hospitals

業界

Gen Med & Surgical Hospitals

ウェブサイト

www.merus.nl

本社

Utrecht, Utrecht, Nld

設立

Merus NV is listed in the Gen Med & Surgical Hospitals sector of the ナスダック市場 with ticker MRUS. The last closing price for Merus NV was US$40.40. Over the last year, Merus NV shares have traded in a share price range of US$ 33.8301 to US$ 61.61.

Merus NV currently has 68,463,681 shares in issue. The market capitalisation of Merus NV is US$2.77 billion.

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+;...

Form 8-K - Current report

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1Merus and...

Form 8-K - Current report

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full...

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.47	1.175	40	41.82	39.22	560162	40.49868238	CS
4	-1.49	-3.55100095329	41.96	47.75	37.77	702062	41.09347035	CS
12	-8.53	-17.4081632653	49	55.39	37.77	628354	43.73040276	CS
26	-14.38	-26.2169553327	54.85	56.39	37.77	554634	47.39759235	CS
52	6.4	18.7848547109	34.07	61.61	33.8301	683222	48.91022242	CS
156	16.71	70.3282828283	23.76	61.61	12.03	444208	35.79226809	CS
260	23.27	135.290697674	17.2	61.61	10.18	345377	32.67451826	CS

MRUS - Frequently Asked Questions (FAQ)

What is the current Merus NV share price?

The current share price of Merus NV is US$ 40.47

How many Merus NV shares are in issue?

Merus NV has 68,463,681 shares in issue

What is the market cap of Merus NV?

The market capitalisation of Merus NV is USD 2.77B

What is the 1 year trading range for Merus NV share price?

Merus NV has traded in the range of US$ 33.8301 to US$ 61.61 during the past year

What is the reporting currency for Merus NV?

Merus NV reports financial results in USD

What is the latest annual turnover for Merus NV?

The latest annual turnover of Merus NV is USD 43.95M

What is the latest annual profit for Merus NV?

The latest annual profit of Merus NV is USD -154.94M

What is the registered address of Merus NV?

The registered address for Merus NV is UPPSALALAAN 17, UTRECHT, UTRECHT, 3584 CT

What is the Merus NV website address?

The website address for Merus NV is www.merus.nl

Which industry sector does Merus NV operate in?

Merus NV operates in the GEN MED & SURGICAL HOSPITALS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
RNAZTransCode Therapeutics Inc	US$ 15.10 (121.08%)	28.14M
SLXNSilexion Therapeutics Corporation	US$ 1.1211 (93.29%)	185.55M
TOIIWOncology Institute Inc	US$ 0.0498 (66.00%)	17.2k
HEPAHepion Pharmaceuticals Inc	US$ 0.2575 (56.06%)	256.82M
TRIBTrinity Biotech PLC	US$ 1.1605 (52.70%)	102.94M
STSSSharps Technology Inc	US$ 0.4282 (-70.67%)	13.4M
LPTXLeap Therapeutics Inc	US$ 0.66705 (-70.35%)	9.25M
SABSSAB Biotherapeutics Inc	US$ 2.2391 (-48.64%)	985.38k
MGOLMGO Global Inc	US$ 0.1599 (-43.50%)	19M
INKTMiNK Therapeutics Inc	US$ 5.50 (-37.78%)	145.38k
NVDANVIDIA Corporation	US$ 125.59 (6.05%)	350.93M
HEPAHepion Pharmaceuticals Inc	US$ 0.2554 (54.79%)	256.84M
SLXNSilexion Therapeutics Corporation	US$ 1.125 (93.97%)	185.55M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.5227 (26.84%)	178.8M
TRIBTrinity Biotech PLC	US$ 1.1605 (52.70%)	102.94M